Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Molnunat 200mg Tablet: Revolutionizing COVID-19 Treatment
Introduction:
Molnunat 200mg Tablet marks a groundbreaking advancement as the first oral antiviral medication formulated to combat mild to moderate COVID-19 in adults. By impeding viral replication, it effectively reduces viral load and mitigates disease severity. This medication received emergency use approval from Indian drug regulatory authorities on December 28, 2021.
Key Information:
Type of Medication: Oral Antiviral
Approval Status: Granted emergency use approval by Indian regulatory authorities (December 28, 2021), as well as by the U.S. Food and Drug Administration (FDA) and the UK regulatory agency.
Uses:
Treatment of Mild to Moderate COVID-19: Molnunat 200mg Tablet is specifically indicated for individuals exhibiting mild to moderate symptoms of Coronavirus disease (COVID-19) who are at high risk of developing severe complications. High-risk factors may include obesity, advanced age (>60 years), diabetes mellitus, and heart diseases. It is not recommended for patients requiring immediate hospitalization due to COVID-19.
Mechanism of Action:
Antiviral Properties: Molnunat 200mg Tablet functions as an antiviral agent by inhibiting the replication of the SARS-CoV-2 virus. By impeding viral replication, it prevents the production of new viral copies, thereby reducing the viral load in the body.